Morphine
Duramorph, Embeda, Infumorph, Mitigo, Morphine, Ms Contin (morphine) is a small molecule pharmaceutical. Morphine was first approved as Duramorph pf on 1984-09-18. It is used to treat dyspnea and intractable pain in the USA. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor and kappa-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Infumorph, Mitigo, Morphine, Ms contin (discontinued: Arymo, Astramorph, Avinza, Depodur, Kadian, Morphine, Oramorph)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Morphine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MORPHINE SULFATE | Fresenius Kabi | N-204223 RX | 2013-10-30 | 3 products, RLD, RS |
| DURAMORPH PF | Hikma Pharmaceuticals | N-018565 RX | 1984-09-18 | 2 products, RLD, RS |
| INFUMORPH | Hikma Pharmaceuticals | N-018565 RX | 1991-07-19 | 2 products, RLD, RS |
| MORPHINE SULFATE | Hikma Pharmaceuticals | N-022195 RX | 2008-03-17 | 3 products, RLD |
| MORPHINE SULFATE | Hikma Pharmaceuticals | N-022207 RX | 2008-03-17 | 2 products, RLD, RS |
| MORPHINE SULFATE | Hospira | N-202515 RX | 2011-11-14 | 5 products, RLD |
| MS CONTIN | Purdue Pharma | N-019516 RX | 1987-05-29 | 5 products, RLD |
Show 12 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avinza | New Drug Application | 2011-09-22 |
| depodur | 2008-01-10 | |
| duramorph | New Drug Application | 2025-12-31 |
| embeda | New Drug Application | 2010-01-22 |
| infumorph 200 infumorph 500 | New Drug Application | 2025-12-31 |
| kadian | New Drug Application | 2011-06-15 |
| mitigo | ANDA | 2026-02-19 |
| morphine sulfate | ANDA | 2026-04-03 |
| morphine sulfate extended-release | 2007-09-27 | |
| morphine sulfate morphine sulfate | New Drug Application | 2024-10-15 |
Show 2 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MORPHINE SULFATE, MORPHINE SULFATE, HIKMA | |||
| 2024-06-02 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Morphine Sulfate, Morphine Sulfate, Fresenius Kabi Usa | |||
| 9072781 | 2034-03-12 | DP | |
| 9192608 | 2034-03-12 | U-43, U-55 | |
| 9248229 | 2034-03-12 | DP | |
| Morphine Sulfate, Arymo Er, Zyla | |||
| 9044402 | 2033-07-01 | DP | U-1556 |
| 9549899 | 2033-07-01 | DP | U-1556 |
| Morphine Sulfate / Naltrexone Hydrochloride, Embeda, Alpharma Pharms | |||
| 8623418 | 2029-11-07 | U-1640 | |
| 7815934 | 2027-12-12 | DP | |
| 7682633 | 2027-06-19 | U-1510 | |
| 7682634 | 2027-06-19 | DP | |
| 8158156 | 2027-06-19 | U-1510 | |
| 8846104 | 2027-06-19 | DP | |
| 8877247 | 2027-06-19 | DP | |
| 8685443 | 2025-07-03 | U-1508 | |
| 8685444 | 2025-07-03 | DP | |
| Morphine Sulfate, Morphabond Er, Ohemo Life | |||
| 7955619 | 2028-08-12 | DP | |
| 10314788 | 2028-08-12 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07D: Antipropulsives
— A07DA: Antipropulsives
— A07DA52: Morphine, combinations
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AA: Natural opium alkaloid analgesics
— N02AA01: Morphine
— N02AA51: Morphine, combinations
— N02AG: Opioids in combination with antispasmodics
— N02AG01: Morphine and antispasmodics
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05D: Cough suppressants, excl. combinations with expectorants
— R05DA: Opium alkaloids and derivatives, cough suppressants
— R05DA05: Opium alkaloids with morphine
Clinical
Clinical Trials
2682 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 16 | 40 | 78 | 196 | 258 | 574 |
| Pain | D010146 | EFO_0003843 | R52 | 29 | 48 | 83 | 81 | 90 | 319 |
| Acute pain | D059787 | — | R52 | 12 | 22 | 27 | 35 | 32 | 124 |
| Agnosia | D000377 | EFO_0007136 | F88 | 5 | 10 | 20 | 41 | 49 | 120 |
| Analgesia | D000698 | — | — | 4 | 5 | 5 | 26 | 61 | 100 |
| Chronic pain | D059350 | — | — | 11 | 13 | 22 | 25 | 29 | 96 |
| Neoplasms | D009369 | — | C80 | 11 | 26 | 25 | 9 | 20 | 82 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 7 | 10 | 23 | 14 | 27 | 79 |
| Healthy volunteers/patients | — | — | — | 59 | 4 | — | 5 | 8 | 73 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 23 | 19 | 9 | 9 | 13 | 70 |
Show 334 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhabdomyosarcoma | D012208 | — | — | 9 | 10 | 3 | — | 4 | 20 |
| Seizures | D012640 | — | G40.4 | 1 | 3 | 3 | — | 10 | 16 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 4 | 3 | — | 7 | 13 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | 11 | 12 |
| Cardiac surgical procedures | D006348 | — | — | — | 1 | 4 | — | 6 | 11 |
| Sarcoma | D012509 | — | — | 3 | 4 | 1 | — | 4 | 10 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 2 | — | 7 | 10 |
| Leukemia | D007938 | — | C95 | — | 2 | 5 | — | 2 | 9 |
| Heroin dependence | D006556 | EFO_0004240 | — | 2 | 2 | 2 | — | 2 | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | 3 | — | 2 | 7 |
Show 78 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | 8 | 9 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | 1 | — | — | 4 | 6 |
| Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | 5 | 6 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 3 | — | — | — | 5 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | 4 | — | — | — | 5 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | — | 4 | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 2 | — | — | 3 | 5 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 2 | — | — | 2 | 4 |
| Drug overdose | D062787 | — | — | 3 | 1 | — | — | 1 | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 1 | — | — | 2 | 4 |
Show 81 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart arrest | D006323 | EFO_0009492 | I46 | 1 | — | — | — | 2 | 3 |
| Hypercapnia | D006935 | — | — | 3 | — | — | — | — | 3 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 2 | — | — | — | 1 | 3 |
| Recreational drug use | D000084783 | — | — | 3 | — | — | — | — | 3 |
| Hepatitis | D006505 | — | K75.9 | 1 | — | — | — | 1 | 2 |
| Gastric emptying | D005746 | — | — | 1 | — | — | — | 1 | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | 1 | 2 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | — | 1 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | 1 | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
Show 33 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatectomy | D006498 | — | — | — | — | — | — | 6 | 6 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 6 | 6 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 4 | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 4 | 4 |
| Reperfusion injury | D015427 | — | — | — | — | — | — | 4 | 4 |
| General anesthesia | D000768 | — | — | — | — | — | — | 4 | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 4 | 4 |
| Sexual trauma | D000082002 | — | — | — | — | — | — | 4 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 3 | 3 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 3 | 3 |
Show 321 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Morphine |
| INN | — |
| Description | Morphine is a morphinane alkaloid that is a highly potent opiate analgesic psychoactive drug. Morphine acts directly on the central nervous system (CNS) to relieve pain but has a high potential for addiction, with tolerance and both physical and psychological dependence developing rapidly. Morphine is the most abundant opiate found in Papaver somniferum (the opium poppy). It has a role as an opioid analgesic, a mu-opioid receptor agonist, a plant metabolite, an environmental contaminant, a xenobiotic, a vasodilator agent, an anaesthetic, a drug allergen and a geroprotector. It is an organic heteropentacyclic compound, a tertiary amino compound and a morphinane alkaloid. It is a conjugate base of a morphine(1+). It derives from a hydride of a morphinan. |
| Classification | Small molecule |
| Drug class | Opioid |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5 |
Target
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Arymo – Zyla Life Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Morphine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Morphine
+
Naltrexone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 32,398 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avinza, Duramorph, Embeda, Infumorph 200 infumorph 500, Kadian, Mitigo, Morphine sulfate, Morphine sulfate morphine sulfate, Ms contin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
161,974 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use